I[NTRODUCTION]{.smallcaps} {#sec1-1}
==========================

Conventional antiplatelet treatment (CAT) with clopidogrel in addition to aspirin has been recommended for patients undergoing percutaneous coronary intervention (PCI) since 2002.\[[@ref1]\] However, patients have significantly varied responses to clopidogrel, and clopidogrel low response (CLR) is an independent risk factor of adverse clinical outcomes in patients undergoing PCI.\[[@ref2][@ref3][@ref4][@ref5][@ref6]\]

A few randomized controlled trials (RCTs) investigated the efficacy of intensified antiplatelet treatment (IAT) guided by platelet function assays, but the results were controversial. The Gauging Responsiveness with a VerifyNow Assay-Impact on Thrombosis and Safety (GRAVITAS)\[[@ref7]\] and Testing Platelet Reactivity in Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy with Prasugrel (TRIGGER-PCI)\[[@ref8]\] trials showed that patients with CLR did not benefit from IAT guided by the VerifyNow Assay. However, several other randomized trials reported that IAT significantly reduced the incidence of stent thrombosis (ST) or composite endpoints compared to CAT for patients with CLR undergoing stent implantation.\[[@ref9][@ref10]\] Accordingly, we conducted this meta-analysis to elucidate whether patients with CLR can benefit from IAT guided by platelet function assays.

M[ETHODS]{.smallcaps} {#sec1-2}
=====================

Search strategy {#sec2-1}
---------------

The literature was scanned using computerized searches of PubMed, the Cochrane Library, and the Chinese Medical Journal Network databases from their establishment to September 9, 2014. The search terms included three parts, CLR, clinical events, and method of platelet function test. The search terms for CLR included clopidogrel, low response or no response or high on-treatment platelet reactivity (HOPR) or high residual platelet reactivity or high platelet reactivity or resistance. The search terms for clinical events included death or myocardial infarction (MI) or ST or bleeding. The search terms for method of platelet function test included VerifyNow or light transmission aggregation (LTA) or LTA or aggregometer or aggregometry or multiple electrode aggregometry (MEA) or multiplate analyzer or thrombelastography (TEG) or vasodilator-stimulated phosphoprotein (VASP) or LTA or TEG or VASP or MEA or platelet function analyser-100. The article type was limited to RCTs. No language restriction was enforced.

Selection of studies and data extraction {#sec2-2}
----------------------------------------

Studies were selected according to the following criteria: (1) studies that recruited patients with coronary artery disease (CAD) undergoing PCI and initially treated with aspirin plus clopidogrel; (2) studies that identified CLR by platelet function assays; (3) studies that randomly assigned the CLR patients into CAT or IAT arms; and (4) studies that reported clinical adverse events, including cardiovascular (CV) death, nonfatal MI, ST, or bleeding.

A total of 397 papers were initially screened, and 132 papers remained after limiting the article type to clinical trials. Finally, 11 papers that met the study criteria were identified. An additional two papers were included after reviewing the citations of the screened papers.\[[@ref11][@ref12]\] The details of the paper selection are described in [Figure 1](#F1){ref-type="fig"}. Two experienced authors (Xu and Zhang) independently extracted the following data from the selected studies: author name and year of publication, study design, clinical diagnosis of participants, type of stent implanted, method of platelet function assay, cut-off line of HOPR, number of patients randomized, the strategy of treatment adjustment, duration of follow-up, and clinical outcomes. Disagreements were resolved by discussion or consultation with a third reviewer (Li).

![Flow diagram of literature search of this meta-analysis. CLR: Clopidogrel low response.](CMJ-129-984-g001){#F1}

Quality assessment {#sec2-3}
------------------

The quality of the recruited studies was assessed using the modified Jadad scale,\[[@ref13]\] which is based on methods of randomization, allocation concealment, blinding, and loss to follow-up. The total Jadad score was 7, which was based on a score of 2 for randomization, a score of 2 for allocation concealment, a score of 2 for blinding, and a score of 1 for the description of withdrawals and dropouts. We defined low-quality studies as those with a score of 1--3 and high-quality studies as those with a score of 4--7.\[[@ref14][@ref15]\]

Statistical analysis {#sec2-4}
--------------------

A conventional meta-analysis was performed using Review Manager 5.0.0 (The Cochrane Collaboration, Oxford, England), and a cumulative meta-analysis was performed using STATA 12.0 (Lakeway Drive, College Station, Texas, USA). A subgroup meta-analysis was performed for different platelet function assays. The results are presented as the incidence of outcomes, relative risk (*RR*), 95% confidence intervals (*CI*s), and *P* value. The Cochran *Q*-test and the *I^2^* test (with 95% *CI*s) were used to assess heterogeneity. A fixed-effects model was used if *I^2^* \< 50%, and a random-effects model was used if *I^2^* ≥ 50%. Publication bias was analyzed using funnel plots and was quantified by Egger\'s test. A value of *P* \< 0.05 was considered statistically significant.

R[ESULTS]{.smallcaps} {#sec1-3}
=====================

Characteristics of the included studies {#sec2-5}
---------------------------------------

Thirteen RCTs with 5111 CLR patients were finally recruited, and the characteristics of these studies are summarized in [Table 1](#T1){ref-type="table"}. Assessment of the methodological quality using the modified Jadad scale demonstrated that all 13 studies were ranked as high quality \[[Table 2](#T2){ref-type="table"}\]. The sample sizes of the studies ranged from 44 to 2214, and the participants were aged from 45 to 80 years. Platelet function assays, including the VerifyNow P2Y12, MEA, LTA, TEG, and VASP were used in the recruited studies. In total, 2695 patients were randomly allocated to the IAT arm and 2416 patients to the CAT arm. The follow-up duration ranged from 1 to 12 months, with a mean follow-up period of 5.69 ± 4.60 months.

###### 

Characteristics of included studies

  Authors                                   Design   Participant diagnosis                                    Platelet function assay   Cutoff line for HOPR         Number of patients with HOPR   Number of patients in IAT group   Number of patients in CAT group   Intensified antiplatelet treatment                            Follow-up duration (months)
  ----------------------------------------- -------- -------------------------------------------------------- ------------------------- ---------------------------- ------------------------------ --------------------------------- --------------------------------- ------------------------------------------------------------- -----------------------------
  Aradi*et al*. 2011^\[[@ref16]\]^          RCT      Stable angina                                            LTA                       LTA ≥34%                     74                             36                                38                                Clopidogrel 150 mg                                            12
  Ari*et al*. 2012^\[[@ref17]\]^            RCT      CAD                                                      VerifyNow                 Inhibition value \<40%       94                             47                                47                                Clopidogrel 150 mg                                            6
  Bonello*et al*. 2008^\[[@ref18]\]^        RCT      Refractory angina pectoris, silent ischemia, or NSTEMI   VASP                      PRI \>50%                    162                            78                                84                                Clopidogrel 600--2400 mg                                      1
  Bonello*et al*. 2009^\[[@ref9]\]^         RCT      Refractory angina pectoris, silent ischemia, or NSTEMI   VASP                      PRI ≥50%                     429                            215                               214                               Clopidogrel 600--2400 mg                                      1
  Cuisset*et al*. 2008^\[[@ref11]\]^        RCT      Sable angina or with a positive coronary function test   LTA                       LTA \>70%                    149                            74                                75                                Group IIb/IIIa antagonist (abciximab)                         1
  Guan*et al*. 2012^\[[@ref12]\]^           RCT      ACS (refractory angina pectoris, NSTEMI, or STEMI)       LTA                       LTA \>55%                    840                            560                               280                               Clopidogrel 300 mg, then cilostazol 50--100 mg if LTA \>55%   1
  Price*et al*. 2011^\[[@ref7]\]^           RCT      Stable CAD, NSTE-ACS, or STEMI                           VerifyNow                 PRU ≥230                     2214                           1109                              1105                              Clopidogrel 600 mg LD, 150 mg daily for 6 months              6
  Gremmel*et al*. 2012^\[[@ref19]\]^        RCT      CAD                                                      VerifyNow VASP MEA        PRU \>235 PRI \>50% AU ≥47   44                             21                                23                                Clopidogrel 150 mg                                            3
  Tang*et al*. 2012^\[[@ref20]\]^           RCT      CAD                                                      TEG                       Inhibition rate \<50%        60                             30                                30                                Clopidogrel 150 mg                                            12
  Trenk*et al*. 2012^\[[@ref8]\]^           RCT      Stable CAD                                               VerifyNow                 PRU \>208                    423                            212                               211                               Prasugrel 10 mg                                               6
  Wang*et al*. 2010^\[[@ref21]\]^           RCT      Refractory angina pectoris, silent ischemia, or NSTEMI   VASP                      PRI ≥50%                     298                            147                               151                               Clopidogrel 75--375 mg                                        12
  Paarup Dridi*et al*. 2015^\[[@ref10]\]^   RCT      Stable angina pectoris or non-ST elevation ACS           MEA                       Multiplate- ADP \>70 U       237                            123                               114                               Prasugrel, ticagrelor, or clopidogrel 150 mg                  1
  Samardzic*et al*. 2014^\[[@ref22]\]^      RCT      ACS                                                      MEA                       Platelet reactivity ≤46 U    87                             43                                44                                Increasing clopidogrel dose                                   12

RCT: Randomized clinical trials; HOPR: High on_treatment platelet reactivity; IAT: Intensified antiplatelet treatment; CAT: Conventional antiplatelet treatment; NSTEMI: Non-ST-segment elevation myocardial infarction; STEMI: ST-segment elevation myocardial infarction; CAD: Coronary artery disease; ACS: Acute coronary syndrome; PCI: Percutaneous coronary intervention; LD: Loading dose; LTA: Light transmission aggregometry; VASP: Vasodilator-stimulated phosphoprotein; MEA: Multiple electrode aggregometry; PRU: P2Y12 reaction units; PRI: Platelet reactivity index; AU: Aggregation unit; TEG: Thrombelastography; ADP: Adenosine diphosphate.

###### 

Quality assessment of included studies

  Authors                               Year   Quality assessment               
  ------------------------------------- ------ -------------------- --- --- --- ---
  Aradi*et al*.^\[[@ref16]\]^           2011   2                    2   2   1   7
  Ari*et al*.^\[[@ref17]\]^             2012   1                    2   0   1   4
  Bonello*et al*.^\[[@ref18]\]^         2008   1                    1   2   1   5
  Bonello*et al*.^\[[@ref9]\]^          2009   1                    1   2   1   5
  Cuisset*et al*.^\[[@ref11]\]^         2008   1                    2   0   1   4
  Guan*et al*.^\[[@ref12]\]^            2012   1                    2   0   1   4
  Price*et al*.^\[[@ref7]\]^            2011   2                    2   2   1   7
  Gremmel*et al*.^\[[@ref19]\]^         2012   0                    1   2   1   4
  Tang*et al*.^\[[@ref20]\]^            2012   1                    2   0   1   4
  Trenk*et al*.^\[[@ref8]\]^            2012   1                    2   2   1   6
  Wang*et al*.^\[[@ref21]\]^            2010   1                    1   2   1   5
  Paarup Dridi *et al*.^\[[@ref10]\]^   2014   1                    2   2   0   5
  Samardzic*et al*.^\[[@ref22]\]^       2014   2                    2   0   1   5

For the numbers, 2 indicates that the method of randomization or concealed allocation or blinding was described in the paper, and it was appropriate; 1 indicates that the method of randomization or concealed allocation or blinding or withdrawals and dropouts were described but were inappropriate; 0 indicates that randomization, concealed allocation, blinding or withdrawals, and dropouts were not mentioned in the paper.

Meta-analysis results {#sec2-6}
---------------------

**Heterogeneity assessment**

The studies were homogeneous when evaluated for the heterogeneity of both a single event and the combined events. Similarly, the studies showed homogeneity when evaluated for the heterogeneity of different platelet function assays, such as LTA, VerifyNow, and MEA, except for the studies that showed heterogeneity in the VASP data (I^2^= 80%), in which the random-effects model was used for the VASP analysis. The funnel plots for CV death, nonfatal MI, ST, and bleeding are presented in Supplementary Figure 1.

###### 

Funnel plots for evaluating publication bias of clinical events. (a-d) Represent CV death, nonfatal MI, ST, and bleeding, respectively. X axis shows the *RR* value of effect size from each study. Y axis shows the standard error (SE) of log (*RR*) of effect size from each study. CV: Cardiovascular; MI: Myocardial infarction; ST: Stent thrombosis *RR*: Risk ratio.

###### 

Click here for additional data file.

**Risk ratio for ischemic events and bleeding**

The incidence of combined ischemic endpoints was significantly lower in the IAT arm compared to the CAT arm (*RR* = 0.45, 95% *CI*: 0.36--0.57, *P* \< 0.000,01) \[[Figure 2](#F2){ref-type="fig"}\]. Separately, the incidence of CV death was significantly lower in the IAT arm compared to the CAT arm (*RR* = 0.46, 95% *CI*: 0.28--0.75, *P* = 0.002). The incidence of MI was significantly lower in the IAT arm compared to the CAT arm (*RR* = 0.49, 95% *CI*: 0.35--0.69, *P* \< 0.0001), and the incidence of ST was also significantly lower in the IAT arm compared to the CAT arm (*RR* = 0.44, 95% *CI*: 0.27--0.73, *P* = 0.001). The incidence of bleeding was comparable between the two arms (*RR* = 1.05, 95% *CI*: 0.86--1.27, *P* = 0.65) \[[Figure 3](#F3){ref-type="fig"}\].

![Forest plots for the effect of IAT versus CAT. (a-d) Represent for CV death, nonfatal MI, ST, and the combined endpoints, respectively. IAT: Intensified antiplatelet treatment; CAT: Conventional antiplatelet treatment; CV: Cardiovascular; MI: Myocardial infarction; ST: Stent thrombosis; *CI*: Confidence interval.](CMJ-129-984-g002){#F2}

![Forest plot for the effect of IAT versus CAT on bleeding. IAT: Intensified antiplatelet treatment; CAT: Conventional antiplatelet treatment; *CI*: Confidence interval.](CMJ-129-984-g003){#F3}

Cumulative meta-analyses results {#sec2-7}
--------------------------------

Cumulative meta-analyses were performed to evaluate the effectiveness of IAT sorted by year. The results showed that the cumulative effect of IAT on the incidence of combined endpoints was superior to that of CAT from the initial trial in 2008 (*RR* = 0.40, 95% *CI*: 0.23--0.70). Later trials showed a consistent and significant benefit of IAT \[[Figure 4a](#F4){ref-type="fig"}\]. If the trials were sorted by the population size, the overall effect of IAT remained relatively stable with similar point estimates, whereas the later studies had an increased population size and narrowed the *CI*s \[[Figure 4b](#F4){ref-type="fig"}\].

![Cumulative meta-analysis sorted by year (a) and sample size (b) to show the effect of IAT versus CAT on the combined endpoints. *RR*: Risk ratio; *CI*: Confidence interval.](CMJ-129-984-g004){#F4}

Subgroup meta-analysis results {#sec2-8}
------------------------------

Trials were grouped according to different methods of platelet function assay. Subgroup analysis showed that the combined endpoints were significantly decreased in the IAT arm compared to the CAT arm as guided by the LTA and MEA (*P* = 0.004 and *P* \< 0.000,01, respectively) \[Figure [5a](#F5){ref-type="fig"}--[5d](#F5){ref-type="fig"}\]. One trial adopted TEG to determine the IAT, which resulted in decreased combined endpoints in the IAT arm compared to the CAT arm \[*P* = 0.04; [Figure 5e](#F5){ref-type="fig"}\]. However, there were no significant differences in the combined endpoints between the two arms guided by either VASP or VerifyNow \[*P* = 0.09 and *P* = 0.18, respectively; Figure [5b](#F5){ref-type="fig"} and [5c](#F5){ref-type="fig"}\].

![Subgroup analysis according to platelet function assays. LTA: Light transmission aggregometry subgroup (a); VASP: Vasodilator-stimulated phosphoprotein subgroup (b); VerifyNow and MEA: Multiplate analyzer subgroup (c) and subgroup (d); TEG: Thrombelastography hemostasis analyzer subgroup (e). IAT: Intensified antiplatelet treatment; CAT: Conventional antiplatelet treatment; *CI*: Confidence interval.](CMJ-129-984-g005){#F5}

D[ISCUSSION]{.smallcaps} {#sec1-4}
========================

This study revealed that platelet function assay-guided IAT significantly decreased the incidences of CV death, MI, and ST without an increased risk of bleeding compared to CAT in CAD patients undergoing PCI. The result of this meta-analysis might provide evidence-based science for clinical guideline development.

CLR is an independent risk factor for adverse clinical outcomes.\[[@ref3][@ref23][@ref24]\] Theoretically, any intensified antiplatelet therapy that improves the platelet response should improve the patient\'s clinical outcome. However, most studies investigating the benefits of IAT yielded negative results,\[[@ref7][@ref12][@ref19]\] and several critical issues regarding the design of these trials have been noted. First, the participants recruited in these studies were in stable condition. In the GRAVITAS, non-ST-segment elevation myocardial infarction and ST-segment elevation myocardial infarction, patients accounted for only 10% and 0.4% of the study population, respectively.\[[@ref7]\] In the TRIGGER-PCI, 100% of the participants were stable CAD patients, and the low incidence of the primary endpoint (2.3% vs. the expected 7% rate) resulted in the early discontinuation of the trial.\[[@ref8][@ref25]\] Therefore, the low-risk population with a low incidence of primary endpoints might contribute to the negative results of these trials. Second, randomization was performed late during the GRAVITAS and TRIGGER-PCI trials (12--24 h after PCI and 2--7 h after the patients were first administered clopidogrel, respectively); therefore, some periprocedural events might have not been included in these trials. Third, inappropriate cutoff values for CLR with less IAT might also contribute to the negative results. In the GRAVITAS trial, CLR was defined as ≥230 platelet reaction units (PRU) using the VerifyNow P2Y12 test.\[[@ref7]\] However, Price *et al*.\[[@ref26]\] performed a *post hoc* analysis and found that using PRU \<208 as a cutoff level, the IAT was associated with a lower risk of adverse clinical events. Finally, CLR patients did not receive an ideal IAT regimen in most trials. Currently available potent antiplatelet agents, such as ticagrelor and prasugrel, were not available or used in most of the recruited trials. In fact, most studies used an increased dose of clopidogrel as IAT \[[Table 1](#T1){ref-type="table"}\]; however, 40% of the CLR patients remained low response to clopidogrel although the dose of clopidogrel was doubled.\[[@ref25]\]

Our study results were verified by cumulative meta-analysis, which indicated that IAT significantly diminished the major CV events, whereas the study sample size was increased to a statistically reasonable level. However, future studies should also consider recruiting higher risk patients and using more intensified antiplatelet agents. Hopefully, current ongoing studies, such as ANTARCTIC and TROPICAL-ACS, will increase our knowledge of the value of IAT guided by platelet function assays. We performed a subgroup analysis on different platelet function assays and found that LTA and MEA-guided IATs improved the combined endpoints of the CLR patients, whereas VASP- and VerifyNow-guided IAT did not. These results are consistent with reports that LTA and MEA are highly correlated to ischemic events\[[@ref27][@ref28][@ref29][@ref30]\] although Tang *et al*.\[[@ref20]\] found that TEG-guided IAT also decreased the incidence of ischemic CV events compared to CAT.

It should be noted that some important trials were not recruited in our meta-analysis because they did not meet our inclusion criteria. The MEA in Patients Receiving Dual Antiplatelet Therapy to Guide Treatment with Novel Platelet Antagonists (MADONNA) study\[[@ref31]\] found that personalized antiplatelet treatment according to platelet function testing with MEA resulted in an improved efficacy with equal safety compared to the standard treatment. However, it was excluded because it was a cohort study rather than an RCT. Although the Assessment by a Double Randomization of a Conventional Antiplatelet Strategy Versus a Monitoring-guided Strategy for Drug-Eluting Stent Implantation and of Treatment Interruption versus Continuation 1 year after Stenting (ARCTIC) study\[[@ref32]\] was an RCT, it randomized all recruited patients, not only the CLR patients, into the IAT and CAT arms, which did not meet our inclusion criteria.

To the best of our knowledge, only one similar meta-analysis was reported by Aradi *et al*.\[[@ref33]\] However, several differences existed between the study of Aradi *et al*. and ours. First, to ensure the quality of the studies and to diminish the heterogeneity, all RCTs included in our study must randomize the CLR patients into the IAT and CAT arms. The study of Hazarbasanov *et al*.\[[@ref30]\] was recruited in the study of Aradi *et al*., but was excluded in our study for the same reason as the ARCTIC study. We proposed that because both arms involve patients who normally responded to clopidogrel such as in these studies, this would dilute the efficacy of the IAT causing the results to be less reliable. Second, we recruited the latest RCTs\[[@ref12][@ref19][@ref20]\] that were not included in the study of Aradi *et al*. Third, in addition to the conventional meta-analysis, we also performed a cumulative meta-analysis, which further confirmed our study results.

Our study had potential limitations. First, different platelet function assays were using in the recruited studies. However, the studies were homogeneous for the evaluation of heterogeneity of different platelet function assays, such as LTA and VerifyNow. Although the studies showed heterogeneity in the VASP analysis, the random-effects model was used for the VASP analysis. Second, the cutoff values for CLR varied between studies \[[Table 1](#T1){ref-type="table"}\], which might result in different strengths of the IATs. Third, the follow-up period of some recruited studies was relatively short (one month), and late adverse events might have not occurred during the study period.

In conclusion, this meta-analysis demonstrates that IAT guided by platelet function assays reduces the risk of CV death, nonfatal MI, and ST without an increased risk of bleeding.

*Supplementary information is linked to the online version of the paper on the Chinese Medical Journal website*.
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